If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
SP doing well at the moment. Better than I expected and delighted to admit it! Ha! Obviously due to CeramycGuard...
On a separate note, Bolflex appear to have had a fire at one of their rubber recycling plants. The place was gutted. Obviously don't want to use a partner's negative as a positive for HAYD but could it lead to a short term spike in demand for graphene enhanced rubber?
Finally, anyone bought any masks lately? If so, have you got the refs available to give us an idea of sales over the past couple of months? Cheers
UiPath set to open up 14%, potentially valuing it over $33 billion
(Reuters) - Automation tech startup UiPath Inc was set to be valued at more than $33 billion in its U.S. market debut on Wednesday, the latest tech company to capitalize on investors' appetite for high-growth stocks.
At 10:51 a.m. ET, the stock was set to open at a range between $62 and $64 per share, up as much as 14% from the offer price of $56 per share.
DG - Ha! Based on your posts, I wondered whether you were a shorter doing the Company down. Obviously not though.
Hopefully today's IPO does have a positive impact. The revised expectation is that they will float on $28bn (https://www.google.com/amp/s/www.cnbc.com/amp/2021/04/20/uipath-ipo-to-raise-nearly-1point5-billion-as-cloud-stocks-retreat.html).
If PRSM file for a US listing following a $28bn UiPath float, we could finally have lift off.
"Dividend
The Board of BATM has resolved to recommend the distribution of a dividend for full year 2020. In accordance with Israeli law, a dividend can only be declared following the publication of the audited annual report and accounts. Accordingly, we will provide further details in due course."
UiPath IPO expected 21 April 2021 - https://www.google.com/amp/s/www.ig.com/uk/trading-strategies/uipath-ipo--how-to-buy-and-short-uipath-shares-210416.amp
Anticipated market cap of c.$25bn on revenue 3.13x PRSM's.
Puts PRSM's potential market cap for US listing at $7.99bn (£5.79bn) at current ex rates.
To repeat what I said on ADVFN earlier:
While Vec's primary focus is on bringing new inhaled medicines to market, if the board can't (or won't) direct resources to meet what will be the largest single spike in global demand for an inhaled medicine since the invention of the inhaler, they all want lining up on Bridlington Pier and machine gunning into the North Sea.
BBC News - Covid: Asthma drug 'speeds up recovery at home'
https://www.bbc.co.uk/news/health-56717486
Hopefully Vec will be at the forefront of the global supply of the inhaled budesonide. Demand will likely rocket, especially in Europe given their dreadful vaccine rollout.
Or you could focus on the negative ?????
You stand to make £115k from the upcoming special div, which pretty much covers your original stake. Fair play to you!
They've got organic growth, management who've proven they can increase market cap and cash at bank for fresh acquisitions. Underperform is a joke of a rating. Jefferies must have a ****load of twitchy shorters on their books, unhappy at their woeful advice.
... at a modest premium. Someone's expecting this to fly.
Rock solid. At this stage, happy to see no dividend being offered. It's cash generative bolt on acquisitions that will make this Company fly. Target 900. With two or three good purchases, we'll be well over a tenner by next results.